The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism.
Muir
Keith W
KW
Institute of Neurological Sciences, Southern General Hospital, Glasgow G51 4TF, UK. k.muir@clinmed.gla.ac.uk
D002986:Clinical Trials as Topic; D017984:Enoxaparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D020521:Stroke / Q000150:complications / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000517:prevention & control*
D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors